Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.
about
Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patientsPrefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis.Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysisTwo-dimensional J-resolved proton MR spectroscopy and prior knowledge fitting (ProFit) in the frontal and parietal lobes of healthy volunteers: assessment of metabolite discrimination and general reproducibility.The effect of insulin infusion on the metabolites in cerebral tissues assessed with proton magnetic resonance spectroscopy in young healthy subjects with high and low insulin sensitivity.Biology and recent brain imaging studies in affective psychoses.Magnetic resonance spectroscopy and schizophrenia: what have we learnt?T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.Magnetic resonance spectroscopy and its applications in psychiatry.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis.Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.Glutamate-mediated excitotoxicity in schizophrenia: a review.Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiationProton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology.Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.The effects of antipsychotic treatment on cerebral structure and function in schizophrenia.Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology.In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders.Imaging genetics of structural brain connectivity and neural integrity markers.Theranostic Biomarkers for SchizophreniaMesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies.Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophreniaProgressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophreniaGlutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia.Proton magnetic resonance spectroscopy in 22q11 deletion syndrome.Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia.Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamineHigher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.Parvalbumin neurons in the entorhinal cortex of subjects diagnosed with bipolar disorder or schizophrenia.Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls.A framework for interpreting functional networks in schizophrenia.Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR SpectAdding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.Phase-adjusted echo time (PATE)-averaging 1 H MRS: application for improved glutamine quantification at 2.89 T.Clinical and cognitive correlates of the proton magnetic resonance spectroscopy measures in chronic schizophrenia.
P2860
Q24803969-D9703BE8-4771-41E1-921D-E9D426444B8AQ30471857-BC599AF7-85DE-40CE-91A8-84B27F55F27AQ30565982-CB5E6639-331C-4A06-BA6C-44B1A2D2B467Q30572951-676A9561-721C-4B2E-A1D8-8EE4671B44D0Q30618184-1D377089-AD0A-48A2-B45A-FE7DCADF0B9CQ30621010-86ABF3AA-ACA2-414B-9711-67CB0CA560DBQ30629018-6774CDF0-7545-4392-B13F-CEC9C6373AA4Q30648464-21A30944-CE7D-42F5-87DF-344148ADFC22Q30684591-07838FE8-659B-4010-9834-5B0973A8058EQ30685335-90709B8F-5922-4E86-85A4-E1048896644DQ30712278-961613BB-01F2-4FE2-9DD8-C15DDC91F0C6Q30732395-4949CFDE-0F29-45E0-B76D-3E5D8664E392Q30845062-5036F4FB-D9EE-4C12-8DC4-2BB77AABE8ADQ30854782-620C730D-E2AC-44CE-9C42-15F317B9D4A1Q30949960-FFDC68DD-62B8-4C73-8225-C3D106592C2FQ30993265-014A14F1-EC2B-4773-B2B9-544F605BB60BQ31001850-34DC4EBD-6F17-43B2-8905-EBD4672351CDQ31120604-C33B102D-D469-4B18-B943-C980FE44388BQ31153621-FFEA16DC-1AB1-4D6F-A85E-E984926D93D7Q32115381-6ED35E51-A79F-4B44-B353-9E1B68D2FAEFQ33516442-05EF08C9-0044-44DA-B4AE-DF6E4846D857Q33624412-A60AB1E1-59B5-4C43-B41F-58AFFA2B270CQ33692860-CB3FCAB1-21E5-45F6-BAD8-E28551457F5EQ33696761-E5CC65F7-6375-4C47-9315-03237557FB7DQ33754399-62BEFE47-443D-4AB9-8B19-CD757A112110Q33891806-4F681347-4F58-4686-8914-7F0C08BE6350Q33955280-9F0517E9-7315-48C3-ADF9-D6B8B6FE5123Q33957510-80F41F74-B843-452A-BAC8-3BB0BD5359CDQ34011793-39C72E53-41A0-4C2D-A094-F45F79F53D4CQ34048560-CDFA72DA-DC01-4B0F-A8F9-AEAFAC7234DCQ34372998-CD9B36F7-3111-4E35-8FEF-B125A25152B0Q34661613-E917B5A2-D867-4811-8774-9C58116D167BQ35158156-5F3137E1-E742-432E-9D1F-B4A7ACB3CB1BQ35970868-DF707563-905D-4184-9EA8-7DB923FD10E2Q36043389-567A4BFA-7539-4B29-9519-C086F0F24EC8Q36049650-D1C4EE26-4C26-4C5D-AF31-A8D90921758BQ36247410-A61C7767-8F72-42FB-A200-0CFDF66EB5DCQ36247426-D9285E12-BB21-4006-AC08-D6020D8FD06AQ36311187-545757FA-607C-40C9-A7A8-CEE0481395D4Q36577350-43187951-615D-4669-A23E-E089F3260B87
P2860
Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Measurement of glutamate and g ...... gnetic resonance spectroscopy.
@en
Measurement of glutamate and g ...... gnetic resonance spectroscopy.
@nl
type
label
Measurement of glutamate and g ...... gnetic resonance spectroscopy.
@en
Measurement of glutamate and g ...... gnetic resonance spectroscopy.
@nl
prefLabel
Measurement of glutamate and g ...... gnetic resonance spectroscopy.
@en
Measurement of glutamate and g ...... gnetic resonance spectroscopy.
@nl
P2093
P1433
P1476
Measurement of glutamate and g ...... gnetic resonance spectroscopy.
@en
P2093
Neufeld RW
Williamson PC
P304
P356
10.1001/ARCHPSYC.1997.01830220085012
P407
P577
1997-10-01T00:00:00Z